NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NiKang Therapeutics

NiKang Therapeutics

Private
Wilmington, DelawareHealthcare & Life Scienceshttps://www.nikangtx.com/

Last Round

Series C

May 26, 2021

Total Funding Raised

$270M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

NiKang Therapeutics is a biotechnology company that discovers and develops innovative small molecule oncology medicines to address unmet medical needs through structure-based drug design.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

small molecule drugsoncology therapeuticsstructure-based drug designtargeted oncologyHIF2α inhibitorundruggable targetsKRAS inhibitorCDK2 inhibitorCDK2 degradersolid tumor therapyclinical-stage biotechPROTAC degraderclear cell renal cell carcinomaccRCCbiotech licensingSHP2 inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NiKang Therapeutics Comparables

Compare NiKang Therapeutics with similar companies based on industry and business-model similarity.

NiKang Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avenzo Therapeutics
78%
Arcus Biosciences
77%
Novartis
74%

NiKang Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 26, 2021
Series BSep 14, 2020
SeedDec 4, 2017

Key People

Founding team and executive leadership

Kelsey Chen

CFO COO, Chief Financial Officer

Executive Team

NiKang Therapeutics Investors

Notable investors and investment history

NiKang Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries C
MatrixSeries B, Series C
Surveyor CapitalSeries C
Janus Henderson GroupSeries C
RA Capital ManagementSeries C
Perceptive AdvisorsSeries C
Octagon Capital AdvisorsSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 96% MoM.

  • May 20, 2026

    Monthly visitors increased 207% MoM.

NiKang Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NiKang Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NiKang Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWilmington, Delaware
Employee Range37
Year Founded2017
Last FundingMay 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.